Midodrine Effect on the Mortality Rates in Septic Shock Patients
- Registration Number
- NCT05778838
- Lead Sponsor
- Noha Mansour
- Brief Summary
Assessing the safety and efficacy of the adjunctive use of midodrine as a vasopressor in septic shock patients by measuring the difference in the mortality rates between control and intervention groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Adult aged 18 years or older diagnosed with septic shock.
- Hypotensive and require IV vasopressor for more than 24 hours.
Exclusion Criteria
- Hypovolemic shock.
- Severe organic heart disease (ejection fraction <30 percent).
- Bradycardia (HR<50 b/m).
- Chronic kidney disease (serum creatinine >2mg/dl).
- Thyrotoxicosis.
- Pheochromocytoma.
- Known allergy to midodrine.
- Unable to administer an oral medication.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Midodrine Oral Tablet Will receive IV vasopressor infusion only Midodrine Midodrine Oral Tablet Will receive oral midodrine 10 mg/ 8 hours in addition to IV vasopressor infusion till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours).
- Primary Outcome Measures
Name Time Method Mortality rates Time Frame: Starting from date of randomization till shock reversal or date of death from any cause, whichever came first,assessed up to 30 days The primary outcome is measuring the difference in ICU mortality rates between control and intervention group.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mansoura University
🇪🇬Mansoura, Egypt